EmbarkNeuro

EmbarkNeuro, formerly known as Ancora Bio, focuses on bringing significant new personalized treatments to patients with mental health disorders. The incidence of major depressive disorder is rising rapidly, largely due to the sharp increase in stress caused by the COVID-19 pandemic. The company is identifying individuals with depression who have potential biomarkers associated with the stress response system (elevated cortisol) and is developing ANC-501 as a new therapy specifically targeting these patients.